Financial PerformanceShares are undervalued despite strong earnings and free cash flow visibility.
Growth And Market PositionInvestments in orthopedics and accelerated acquisitions are expected to sustain double-digit revenue and EBITDA growth at improving margins.
Strategic InitiativesSGRY's robust earnings visibility, bolstered by its organic growth profile, margin expansion potential, and strategic M&A activities, underpins an optimistic outlook.